NICE stiff-arms Alexion's $552K Strensiq; Mylan falls under DOJ scrutiny for generic prices;

> The cost-effectiveness watchdogs at the U.K.'s National Institute for Health and Care Excellence said "no go" to Alexion's ($ALXN) $552,000 price on its new rare disease med Strensiq. Report

> The U.S. Justice Department issued a subpoena to Mylan ($MYL), the most recent of a group of drugmakers to come under scrutiny for prices of their generic meds. Report

> Biofrontera won approval in Switzerland for Ameluz, its new skin cancer med; the drug is also under review at the FDA. Release (PDF)

And Finally... Stallergenes is recalling allergy immunotherapies shipped from a plant in Antony, France, after August 13. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.